USD 0.92
(-3.81%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 17.7 Million USD | -0.47% |
2022 | 21.02 Million USD | 0.38% |
2021 | 20.94 Million USD | -3.21% |
2020 | 21.63 Million USD | -81.03% |
2019 | 114.08 Million USD | 3564.73% |
2018 | 3.11 Million USD | 0.0% |
2017 | - USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 20.03 Million USD | -4.24% |
2024 Q2 | 19.13 Million USD | -4.51% |
2023 Q3 | 21.79 Million USD | -3.73% |
2023 FY | 20.92 Million USD | -0.47% |
2023 Q4 | 20.92 Million USD | -4.01% |
2023 Q2 | 22.64 Million USD | -3.64% |
2023 Q1 | 23.49 Million USD | 11.77% |
2022 FY | 21.02 Million USD | 0.38% |
2022 Q3 | 21.71 Million USD | -2.98% |
2022 Q2 | 22.38 Million USD | 8.75% |
2022 Q1 | 20.58 Million USD | -1.72% |
2022 Q4 | 21.02 Million USD | -3.2% |
2021 Q1 | 21.2 Million USD | 3.8% |
2021 FY | 20.94 Million USD | -3.21% |
2021 Q2 | 20.54 Million USD | -3.11% |
2021 Q4 | 20.94 Million USD | 1.99% |
2021 Q3 | 20.53 Million USD | -0.03% |
2020 Q4 | 20.42 Million USD | 0.0% |
2020 Q3 | - USD | 0.0% |
2020 Q2 | - USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2020 FY | 21.63 Million USD | -81.03% |
2019 Q1 | - USD | 0.0% |
2019 FY | 114.08 Million USD | 3564.73% |
2019 Q4 | - USD | 0.0% |
2018 FY | 3.11 Million USD | 0.0% |
2017 FY | - USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Editas Medicine, Inc. | 36.53 Million USD | 51.546% |
Dynavax Technologies Corporation | 256.91 Million USD | 93.109% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 57.37% |
Perrigo Company plc | 4.07 Billion USD | 99.565% |
Illumina, Inc. | 2.26 Billion USD | 99.217% |
Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.949% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -1670.3% |
Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.815% |
IQVIA Holdings Inc. | 14.23 Billion USD | 99.876% |
Heron Therapeutics, Inc. | 173.75 Million USD | 89.811% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.345% |
Unity Biotechnology, Inc. | 26.99 Million USD | 34.409% |
Waters Corporation | 2.35 Billion USD | 99.248% |
Biogen Inc. | 7.33 Billion USD | 99.759% |
Sangamo Therapeutics, Inc. | 38.1 Million USD | 53.54% |
Evolus, Inc. | 126.54 Million USD | 86.011% |
Cara Therapeutics, Inc. | 43.16 Million USD | 58.99% |
bluebird bio, Inc. | 330.32 Million USD | 94.641% |
Esperion Therapeutics, Inc. | 540.94 Million USD | 96.727% |
FibroGen, Inc. | 170.45 Million USD | 89.614% |
Agilent Technologies, Inc. | 2.73 Billion USD | 99.353% |
Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 15.233% |
Homology Medicines, Inc. | 44.05 Million USD | 59.815% |
Geron Corporation | 85.89 Million USD | 79.391% |
Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 99.262% |
Amicus Therapeutics, Inc. | 445.05 Million USD | 96.022% |
Myriad Genetics, Inc. | 145 Million USD | 87.791% |
Viking Therapeutics, Inc. | 1.26 Million USD | -1305.0% |
Intellia Therapeutics, Inc. | 115.34 Million USD | 84.652% |
Zoetis Inc. | 6.8 Billion USD | 99.74% |
Abeona Therapeutics Inc. | 4.4 Million USD | -302.158% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 99.183% |
BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 98.439% |
Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 97.81% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | 51.262% |
Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 98.782% |
Atara Biotherapeutics, Inc. | 57.87 Million USD | 69.41% |
Verastem, Inc. | 41.55 Million USD | 57.401% |
Nektar Therapeutics | 230.4 Million USD | 92.316% |
Axsome Therapeutics, Inc. | 186.37 Million USD | 90.501% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -475.895% |
Sarepta Therapeutics, Inc. | 1.39 Billion USD | 98.733% |
OPKO Health, Inc. | 326.56 Million USD | 94.579% |
Exelixis, Inc. | 189.94 Million USD | 90.68% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | 95.868% |
Corcept Therapeutics Incorporated | 151 Thousand USD | -11623.841% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 138.4 Million USD | 87.21% |
Imunon, Inc. | 1.13 Million USD | -1453.858% |
Blueprint Medicines Corporation | 774.12 Million USD | 97.713% |
Insmed Incorporated | 1.2 Billion USD | 98.53% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | 98.819% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | 68.936% |
TG Therapeutics, Inc. | 110.79 Million USD | 84.022% |
Incyte Corporation | 38.28 Million USD | 53.762% |
Emergent BioSolutions Inc. | 877.5 Million USD | 97.983% |